Pulmonary Regurgitation clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for

  • COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

    open to all eligible people

    This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.

    at UCLA UCSF

  • ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent

    Sorry, in progress, not accepting new patients

    To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR). Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

    at UCLA UCSF

  • Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

    Sorry, in progress, not accepting new patients

    The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have transitioned into a post-approval study to confirm the long-term functionality of transcatheter implantation of the Medtronic Harmony TPV.

    at UCLA

Our lead scientists for Pulmonary Regurgitation research studies include .

Last updated: